LP
RPRX

LMR Partners’s Repros Therapeutics Inc. RPRX Stock Holding History

LMR Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-23,705
Closed -$170K – 641
2015
Q2 		$170K Buy
+23,705
New +$185K 0.02% 410
2014
Q2 		– Sell
-31,791
Closed -$564K – 664
2014
Q1 		$564K Buy
+31,791
New +$615K 0.08% 119

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

LMR Partners's RPRX Position: Q3 2015 in Review

LMR Partners sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 23,705 shares — an estimated $170K sold.

LMR Partners first reported a position in RPRX in Q1 2014 and held it in 2 quarters. The position peaked at $564K in Q1 2014. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

  • LMR Partners reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
  • LMR Partners sold 23,705 Repros Therapeutics Inc. shares in Q3 2015, an estimated $170K.
  • LMR Partners first reported a position in Repros Therapeutics Inc. in Q1 2014 and held it in 2 quarters.
  • LMR Partners's Repros Therapeutics Inc. position peaked at $564K in Q1 2014.
  • 58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on LMR Partners's 13F filing for Q3 2015, filed 5 Nov 2015.